Think Act Be
Clinical psychologist Seth Gillihan approaches the topic as an interested newcomer with no personal psychedelic experience. Matt clears up the book's title, makes the case that these medicines can be a public good even for people who never take them, and keeps the conversation close to the evidence.
LISTEN
Episode summary
On the Think Act Be podcast, host Seth Gillihan, a clinical psychologist with no personal psychedelic experience, approaches the topic as an interested newcomer. Matt opens by clearing up the book's title, which he says is not a claim that everyone should take a psychedelic. Some people have contraindications, whether from family history, personal history, or medications that interact badly. His point is that these medicines can be a public good even for people who never take them, the way a cancer treatment benefits society at large, and that people deserve good information to decide for themselves or to inform how they vote.
The conversation stays close to the evidence. Matt outlines the conditions researchers are studying, most of which involve repetitive thinking patterns, and points to the MDMA trials for treatment-resistant PTSD, where a large share of participants no longer qualified for the diagnosis after three sessions paired with therapy. He explains the proposed mechanism, a quieting of the default mode network and a window of brain plasticity afterward, and takes up Seth's question about whether the lasting benefit comes from the chemistry or from the insights a person carries out. His honest answer is that the science does not yet settle it, and that he leans toward a biochemical, psychosocial, and spiritual process rather than a magic pill.
Because Seth is a clinician, they spend real time on risk. Matt is careful with language, saying that calling these compounds safe is the wrong word and that the better frame is risk reduction. He walks through the David Nutt harm rankings, where alcohol and tobacco sit far above psilocybin, and through the specific cautions for ketamine, ibogaine, and the classic psychedelics. He names clear contraindications, including schizophrenia, active mania, certain family histories, untreated high blood pressure, and several antidepressant interactions, and points listeners to the pharmacist Ben Malcolm for a personalized read. He adds that anxiety about trying a psychedelic is not itself a reason to avoid one, since nervousness is the norm going in.
They also cover the spiritual side, including Matt's own reconnection with his late mother and the direct religious experience many people report, alongside the three ways Americans currently reach these medicines: a medical model, decriminalization, and religious practice. Matt is frank about the legal reality, that most psychedelics remain illegal while ketamine is the exception, and about the gap that pushes people toward travel, word-of-mouth churches, or underground guides. He returns to his core argument that bringing this into the open would let people access tested medicine and honest guidance rather than working it out in the dark.